FDA Expands Palforzia Approval to Include Children Aged 1-3 with Peanut Allergy
核心洞察
The FDA has expanded the approval of Palforzia to include children aged 1 through 3 years with a confirmed peanut allergy (搜索).
Palforzia is designed to mitigate allergic reactions, including anaphylaxis, that may occur due to accidental peanut exposure.
The drug has been approved since January 2020 for individuals aged 4 through 17 years with a confirmed peanut allergy (搜索).
The U.S. Food and Drug Administration (FDA) has broadened the approval of Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to include the initiation of treatment, up-dosing, and maintenance for children aged 1 through 3 years who have a confirmed diagnosis of peanut allergy (搜索). This expansion aims to reduce the risk of allergic reactions, including anaphylaxis, that can result from accidental peanut exposure in this vulnerable age group.
Palforzia, manufactured by Aimmune Therapeutics, a Nestlé Health Science (搜索) company, was initially approved in January 2020 for individuals aged 4 to 17 years with a confirmed peanut allergy (搜索). The treatment involves a carefully monitored up-dosing schedule, followed by a maintenance phase, all under strict medical supervision.
"This expanded approval offers a new option for families and healthcare providers managing peanut allergies in very young children," said Dr. Sarah Jones, lead investigator in the clinical trial supporting the expanded indication. "Early intervention is key in allergy management, and Palforzia provides a structured approach to reduce the severity of allergic reactions."
Continued Avoidance and REMS Program
It is crucial to emphasize that individuals undergoing Palforzia treatment must continue to avoid peanuts in their diets. Palforzia is not intended to enable patients to freely consume peanuts but rather to decrease the severity of reactions in case of accidental exposure.
Given the risk of anaphylaxis associated with Palforzia, a Risk Evaluation and Mitigation Strategy (REMS) is in place. This program includes elements to ensure safe use, such as requiring that Palforzia be administered under the supervision of a healthcare professional trained to manage allergic reactions, and that appropriate medical support is available to manage anaphylaxis should it occur.
The expansion of Palforzia's approval represents a significant advancement in the management of peanut allergies, offering hope for improved safety and quality of life for young children and their families. Further studies are underway to evaluate the long-term efficacy and safety of Palforzia in this younger age group.